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Abstract Asthma is now widely recognized as a chronic inflammatory condition ofthe airways that requires early 
pharmacological treatment and long-term management. Anti-inflammatory agents, particularly inhaled corticosteroids, 
are currently the most effective long-term preventative medication. Moreover, early intervention with inhaled cortico- 
steroids plays an important role in airway remodelling. Despite significant advances in the understanding ofasthma and its 
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patients whose asthma is not fully controlled with daily inhaled corticosteroid therapy, national guidelines advocate the 
addition of long-acting inhaled /&agonist therapy rather than an increase in dose of inhaled corticosteroids, for the 
treatment of persistent childhood asthma. However, adherence to treatment with asthma medication declines as the 
regimen becomes more complicated, Adherence to therapy and therapy convenience are key to the successful pharma- 
cological management ofasthma, particularly in childrenThe administration of prescribed medication via a single inhaler 
offers a convenient treatment regimen that has the potential to improve adherence to treatment, This paper presents 
data to show that the combined administration of budesonide and formoterol via a single inhaler (Symbicort@ Turbu- 
baler9 is effective and well tolerated in t_he treatment of asthma in children 
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INTRODUCTION 
Over the last 20 years our understanding of the pathol- 
ogy of asthma and its pharmacological management has 
improved greatly. Despite these advances, asthma is a 
serious global health problem, which remains the most 
common chronic disease in childhood and !eading CaIIsF! 0 ----- 
of morbidity. Worldwide it is estimated that the preva- 
lence of asthma in children and young adults varies from 
I to 30% in different populations (1,2). In particular, 
asthma appears to be more prevalent in affluent popula- 
tions. For example, in Australia the prevalence of asthma 
in children is II-30% compared with 2% in Indonesia (2,3). 
Data from the numerous studies which have reported 
the prevalence of this chronic airway disorder should be 
interpreted with caution due to increased awareness and 
variability in the classification and diagnosis of the 
disease. More data are needed from methodologically 
robust studies to clarify this difference in prevalence. 
However, there is no doubt that the prevalence of 
asthma is increasing, with the greatest rise seen in 
children, teenagers and young adults who are therefore 
at highest risk of increased morbidity and death (I). 
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Risk factors for the development of asthma include 
male sex, family and genetic factors, allergic sensitiza- 
tion, respiratory infections, lifestyle factors and outdoor 
and indoor pollution (1,4). There are insufficient data at 
present to confirm the exact cause of the increase in 
prevalence of this disease; however, increasing exposure 
-II_ ._-.__ _ -J _I!___L~_ _ -J ,.I__& I_ I--L_ ~~ ._ Ll__.._I_L to allergens ana climatic ana iiresryie Iactors are rnougnr 
to play a role (2). Asthma has also been linked to an im- 
balance of theThl and Th2 cells involved in immunoregu- 
lation, with an increased Th2/Thl ratio and increased 
levels of ThZ-derived cytokines (e.g. interleukins 4 and 
5) reported in both peripheral blood and bronchial mu- 
cosal tissue of asthmatics. This imbalance, associated 
with local tissue eosinophilia and immunoglobulin-E-de- 
pendent mast cell activation, may be a key factor in re- 
lation to asthma severity (5,6). A better understanding of 
asthma over the last decade has led to a change in the 
management of this disease. It is now recognized that 
early therapeutic intervention with inhaled corticoster- 
oids in mild disease may lead to an improved clinical 
outcome (1!4). Although airways hyper-reactivity was 
previously thought to be the basic cause, the inflam- 
matory nature of this condition is now increasingly 
recognized (3). As a result there has been a shift 
from reliance on short-acting pz-agonists to a more 
widespread early use of inhaled anti-inflammatory 
medications.This change in therapeutic focus is reflected 
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in the various national asthma management guidelines 
(2,356). 
MANAGEMENTAND 
RECOMMENDATIONS FORTREATING 
ASTHMA IN CHILDREN 
The goals of asthma therapy are to maintain normal pul- 
monary function and activity levels, prevent chronic, trou- 
blesome symptoms and recurrent exacerbations, and 
meet patients’and families’expectations of care (3). All of 
these should be achieved with the least amount of medi- 
cation possible and thus the minimum riskof adverse events. 
provement in asthma control in adults and adolescents 
(78). In children aged 6-14 years with chronic asthma, 
there is a small but statistically significant improvement 
in forced expiratory volume in one second (FEVI) when 
compared with placebo (9). Orally administered leuko- 
triene receptor antagonists are mainly recommended in 
the treatment of mild to moderate persistent asthma, 
and as an add-on therapy with inhaled corticosteroids 
(IO). However, their exact position in therapy has not 
been established (5). 
Stepwise approach 
National suidelines take a stenwise aooroach to the man- ---o- ~- ---- _---r ..__ -.TT. _.._.. __ _.._ .._.. 
agement of asthma in infants (< I2 months), young chil- 
dren/preschool (< 5 years) and school-aged children and 
adolescents (5-18 years). Using this approach the num- 
ber of medications and frequency of administrations can 
be increased or decreased as necessary in order to 
achieve or maintain control of asthma. 
The recognition that chronic inflammation may be as- 
sociated with reduced growth of lung function (II), and 
that inflammation of the airways is an early characteris- 
tic of asthma, has led to a change in the pharmacological 
management of asthma. It has been shown that early in- 
tervention with inhaled corticosteroids helps to slow the 
chronic progressive nature of the disease and plays a key 
role in the reduction of permanent lung damage (ll,l2). 
Patients commencing inhaled corticosteroid therapy 
within 2 years of diagnosis show greater improvements 
and preservation of pulmonary function compared with 
those starting treatment after 2 years (12). A long-term 
study in children with asthma confirmed that early inter- 
vention with inhaled budesonide < 400 ,ug day-’ was as- 
sociated with marked improvements in lung function and 
peak flow variability, and may prevent the development 
-r. 01 irreversibie airway obstruction (i3j. Guideiines there- 
fore recommend that infants and children who consist- 
ently require symptomatic relief more than twice a week 
should receive daily anti-inflammatory medication, e.g. 
low-dose inhaled corticosteroids (5). 
If guidelines are to be effective in daily practice, local 
adaptation and patient and healthcare professional edu- 
cation are required (2). A large population-based US 
study in children (O-17years) found that the use of in- 
haled anti-inflammatory medication (including corticos- 
teroid) in those with more severe disease fell short of 
national guidelines during the years when they were ac- 
tively promoted (14). However, a survey of the emerg- 
ency management of childhood asthma in 1994 found that 
50% of physicians believed that the National Institutes of 
Health (NIH) guidelines had changed their handling of 
the disease (15). Compared with results from a similar 
survey in 1988, 82% vs. 21% (P<O.OOl) routinely used 
early glucocorticosteroid administration in their man- 
agement of asthmatic chiidren. 
Treating children with asthma remains a challenge. Un- 
til recently, the lack of a commercially available inhaled 
corticosteroid in the USA for children <4 years explains 
the underuse of this class of drug in young children. 
Furthermore, the diagnosis of asthma in children under 
the age of 3 years is difficult and relies on symptoma- 
tology rather than lung function.To date, the correlation 
between wheezing, which commonly occurs in this age 
group, and development of asthma remains unknown 
and this may also contribute to underdiagnosis. 
RATIONALE FOR THE USE OF 
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A key recommendation of the NIH is that persistent 
asthma is most effectively controlled with daily long- 
term control medication - specifically anti-inflamma- 
tory medication (2). Furthermore, early intervention 
can improve asthma control (16) normalize lung function 
and prevent irreversible damage to the airways (3). 
The efficacy and tolerability of the inhaled glucocorti- 
costeroid budesonide is well established in the treatment 
of childhood asthma (17-19). Compared with other corti- 
costeroids, budesonide has a high ratio of topical to sys- 
temic activity (17). Furthermore, the beneficial effects of 
early inhaled corticosteroid therapy in children are well 
recognized (12,13). Although it is difficult to predict 
...I__LI__.. -1.ll>L__> __&I. .._ .:I, _&:,I I.. ~_~ AL -3 I. 
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hood, respiratory symptoms that are present at 3-4 
years are significantly associated with future asthma 
(12). Early intervention in mild disease may lead to an im- 
proved clinical outcome (4). 
Risk: benefit assessment 
Concerns over potentiai adverse systemic effects of in- 
haled corticosteroids have led to some reservations 
among physicians over the use of this group of drugs in 
children. In particular, effects on growth, bone and the 
hypothalamic pituitary-adrenocortical (HPA) axis have 
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been the topic of much debate. In 1998 the Food and 
Drug Administration (FDA) issued a statement to all 
companies informing them of new labelling requirements 
for inhaled corticosteroids (20). This revised labelling 
alerts prescribers to the possibility of reduced growth 
rate and the need for routine monitoring of growth 
rates, and recommends using the lowest effective dose 
of this group of drugs. 
The evidence for the long-term effects of inhaled cor- 
ticosteroid therapy on growth and bone mineral density 
is conflicting (21) and the clinical relevance of these ef- 
fects has not been established. It is thought that the ad- 
verse effects on growth are dose- and drug-dependent 
and therefore using the lowest possible maintenance 
dose of corticosteroid can minimize the long-term sys- 
temic burden (22). A large placebo-controlled trial involv- 
ing 1041 children with mild to moderate asthma treated 
with budesonide 200,~g or placebo twice daily for 4- 
6years reported a smaii, transient reduction in growth 
velocity (16). Similarly, a recent meta-analysis of studies 
of inhaled corticosteroid treatment of children with 
asthma also reported a reduction in linear growth vel- 
ocity with beclomethasone dipropionate (23). However, 
a recent placebo-controlled study which measured the 
final height of children with asthma reported no effects 
of long-term treatment with budesonide on final height 
(mean duration: 92years) (24). Paediatric studies have 
demonstrated no clinically significant adrenal sup- 
pression or adverse effects related to bone with long- 
term inhaled budesonide (13,25). Furthermore, as noted 
by the NIH guidelines, the potential risks are well 
balanced by the benefits (3). 
Inhaler devices 
Effective delivery of inhaled corticosteroid, and thus 
managing asthma, is one of the particular challenges of 
treating infants and young children. A wide variety of in- 
haler devices are available for the delivery of asthma 
medication and are associated with variable drug deliv- 
ery (26). Failure to respond to treatment may result from 
failure of drug delivery (27) whilst non-compliance and a 
struggling child will have a greater impact (27). A 
patient’s ability to use an asthma inhaler depends on age 
and adequate training in the correct use of the device 
(28). As treatment is long term, the delivery device 
_L_..lJ L_ ^_^.. L_ .._^ sII”“Iu “t: easy LO use. 
Infonts and young children 
Nebulization and holding chambers with a spacer device/ 
face mask are the delivery method of choice in infants 
and young children, as they lack the motor skills to use 
pressurized metered-dose inhalers (pMDI) and dry pow- 
der inhalers (27,29).The use of nebuiizers aiiows drug de- 
livery to very young children through passive inhalation 
(30) and this method is less dependent on co-ordination 
or cooperation than pMDl or dry powder inhalers. The 
use of pMDl with a spacer or a mask is appropriate for 
young children less than 4 or 5 years, while most children 
over 5 years of age can use a turbohaler correctly. The 
BritishThoracic Society and NIH guidelines focus on the 
use of a pMDl with a spacer device or face mask for very 
young children (< 3 years) (3,6,12,27). 
Children 3 5 years ofage 
Apart from pMDl with and without spacers, dry powder 
systems such asTurbuhaler@ are widely used in children 
over 5 years of age for delivering inhaled corticosteroid 
(27). They are simple to use, do not require co-ordi- 
nation of actuation and inhalation and, because of the 
high lung deposition achievable withTurbuhaler@, lower 
doses can be administered. Indeed, the vast majority 
of children aged 4 and 5 years can use Turbuhaler@ 
correctly following individual instruction and training 
at home (31). 
LONG-ACTING P2-AGONIST 
THERAPY IN CHILDREN 
For children with moderate, persistent asthma, the cur- 
rent guidelines recommend the regular use of a long-act- 
ing inhaled Pz-agonist, in addition to a corticosteroid. 
The use of a long-acting &agonist provides extended 
bronchodilation and bronchoprotection, which is particu- 
larly beneficial in controlling exercise-induced broncho- 
constriction and night-time symptoms. 
A l-year study that compared the effects of salmeterol 
and beclomethasone on lung function and symptoms in 
children with mild to moderate asthma concluded that 
the long-acting /&-agonist was statistically significantly 
less effective and should not be used as a monotherapy 
in this patient population (32). Formoterol is a potent 
long-acting /&-agonist, with a rapid onset of action. Its 
efficacy as a bronchodilator which controls asthma 
symptoms in children is already reported in the litera- 
ture (33,34). It is available as a dry powder formulation, 
which can be administered through a single-dose device 
(Aerolizer@) or multiple-dose device (Turbuhale?) (35). 
Formoterol delivered viaTurbuhaler@ provides at least 
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Aerolize?, enabling equivalent efficacy and onset of ac- 
tion with half the dose (36). 
COMBINATION THERAPY IN 
CHILDREN 
Studies in adults indicate that the addition of a long-act- 
ing pz-agonist may be more beneficial than increasing the 
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dose of inhaled corticosteroid in patients with uncon- 
trolled asthma (37). The long-term study by Pauwels et 
a/. confirmed that the combination of budesonide and 
formoterol, via separate inhalers, improved lung func- 
tion and asthma control in adults with moderate to per- 
sistent asthma (38). In these studies, the addition of a 
long-acting /&-agonist to glucocorticosteroid was asso- 
ciated with an improvement in lung function and symp- 
tom control and there was no increase in exacerbation 
rates. However, the evidence in children is less conclusive 
(39) although there are some data favouring this ap- 
proach (40). Since both formoterol and budesonide 
monotherapy are safe and effective in children, the ad- 
ministration of these two drugs in a single inhaler is an 
attractive therapeutic option. 
Adherence to therapy is an important factor in the 
success of asthma treatment and non-adherence to 
treatment regimens may play a role in the lack of im- 
provement in morbidity and mortality of asthma (41). 
Adherence to prescribed inhaled P-agonists and corti- 
costeroids in 24 asthmatic children, tracked over 3 
months, revealed that patients seldom took all of their 
prescribed medication (42). As patients’ symptoms im- 
prove, their use of preventative therapy may also decline. 
A study in 163 children with mild asthma (7-16 years) 
found that compliance with prophylactic asthma treat- 
ment was considerably lower than that reported in daily 
diary cards (43). Patients often link their poor adherence 
to prescribed inhaled corticosteroid therapy to the lack 
of immediate effect (43) unlike the rapid onset of effect 
experienced with short-acting /?z-agonists. This lack of 
adherence to inhaled corticosteroids in preference to 
the short-acting /&-agonists can result in inadequate 
treatment of the underlying inflammatory condition and 
a possible masking of the underlying inflammation (32). 
Clearly, in order to improve adherence to prescribed 
medication there is a need for regimens that are easy to 
use for both the child and family (41,44). It was therefore 
decided to investigate whether combining budesonide 
and formoterol in a single inhaler (Symbicort@Turbuha- 
let-@) could further optimize asthma control in children. 
Furthermore, the administration of glucocorticosteroid 
and long-acting /&-agonist in a single inhaler will improve 
convenience and prevent patients from neglecting the in- 
haled corticosteroid component of their treatment (43). 
As mentioned earlier, the corticosteroid component is 
important in preventing the long-term consequences of 
inflammation. 
CLINICAL STUDIES WITH 
SYMBlCORT@ 
The efficacy and tolerability of Symbicort@ (budesonide 
and formoterol in a single inhaler) have been investigated 
in a double-blind, randomized, parallel-group, multicen- 
tre trial in 286 children with asthma not fully controlled 
with inhaled corticosteroids (45).The children were ran- 
domized to I2 weeks’treatment with either Symbicort@ 
(budesonide/formoterol 80/4.5 ,ug, two inhalations 
twice daily; n = 148) or budesonide (2OOpg twice daily; 
n = 138). Efficacy variables included peak expiratory flow 
(PEF) and FEV, lung function measures. Morning and 
evening PEF increased to a significantly greater extent 
with Symbicort @ than with budesonide alone, relative 
to baseline (both o<O*OOl) (Figure I). FEV, values also 
improved significantly more in the Symbicort@ group, 
measured as mean value for all clinic visits (Figure 2), 
and as mean and maximum FEVi over I2 hours calculated 
in a subgroup of patients at the beginning and end of the 
study (both p <0*05). This study was designed to com- 
pare the effect of budesonide/formoterol and budeson- 
ide alone on lung function; at randomization, patients 
were not symptomatic according to secondary variables 
(symptom score O-3; night-time awakenings and use of 
rescue medication). Children often adapt their lifestyle 
to avoid the symptoms of asthma (46); therefore, signifi- 
cant improvement in symptoms can be difficult to de- 
tect. In terms of adverse events, both treatment groups 
were comparable.This study also supports the beneficial 
effects of combined therapy as opposed to continued 
treatment with inhaled corticosteroid alone. 
The efficacy and tolerability have been further con- 
firmed in a l2-week multinational, double-blind study in 
adults. This study also confirmed that Symbicort@ was 
more effective in improving lung function and controlling 
asthma symptoms than a higher dose of glucocorticos- 
teroid in patients not fully controlled on inhaled corti- 
costeroids alone (47). This potential to reduce the dose 
of corticosteroids and thus the total load with Symbi- 
tort@ warrants further investigation in children. 
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two inhalations twice daily or budesonide lOO,q two inha- 
lations twice daily, P<O.OOl ; b.d: twice daily 
120 
11.5 
SYMBICORT~: CONTROLLING ASTHMA IN CHILDREN S27 
* Symbicort @ 
I-D- Budesonic ;e 
100x I I I 
2 3 4 5 
Visit number 
Figure 2. Forced expiratory volume in I second (FEV,) in children treated with either Symbicort @ 80/4.5 ,ug, two inhalations twice 
daily or budesonide 100 fig, two inhalations twice daily at Visits 2-5.Values are expressed as a percentage ofthose observed during the 
run-in phase (taken as 100%) 
CONCLUSIONS 
Administration of a glucocorticosteroid and long-acting 
/Iz-agonist via a single inhaler is desirable for children and 
their families in order to improve convenience and ad- 
herence, as compliance with maintenance therapy using 
inhaled corticosteroids is often poor.The use of a single 
inhaler also ensures that both the inhaled corticosteroid 
and the long-acting flz-agonist are taken together. The 
new single inhaler Symbicort@ is effective and well toler- 
ated in children and significantly improves lung function 
compared with inhaled corticosteroid monotherapy. 
Furthermore, on the basis of studies in adults, combi- 
nation therapy may enable doctors to reduce the daily 
dose of corticosteroids; this approach would be particu- 
larly advantageous for children, as it helps to minimize 
long-term systemic safety concerns. 
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